Permanent Atrial fibriLLAtion Outcome Study Using Dronedarone on Top of Standard Therapy
A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 3236 participants.
Also called NCT01151137
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 3,236 participants
- Sponsor
- Registry
-
NCT01151137 -
2010-019791-73
-
- Other papers using this trial's data
- Dronedarone in high-risk permanent atrial fibrillation
- Interaction between digoxin and dronedarone in the PALLAS trial
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, Czechia, Denmark, Finland, France, Germany, Greece, Hong Kong SAR China, Hungary, Israel, Italy, Malaysia, Mexico, Netherlands, New Zealand, Norway, Poland, Romania, Russia, Singapore, Slovakia, South Africa, South Korea, Spain, Sweden, Switzerland, Taiwan, Ukraine, United Kingdom
- Registry status
- Terminated
Technical summary
Registry record NCT01151137. Randomized; triple masking; primary purpose treatment. Start 2010-07 (registry gives no type); primary completion 2011-09 (actual). Results posted on 2012-10-26.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Permanent Atrial fibriLLAtion Outcome Study Using Dronedarone on Top of Standard Therapy
- Acronym
- PALLAS
- Condition
- Atrial Fibrillation
- Intervention (Drug)
- Dronedarone
- Intervention (Drug)
- Placebo (for Dronedarone)
- Lead sponsor
- Sanofi
Record details
- Record id
cardio:ct-nct01151137- Content hash
97a97ed116a7c45aea7eeb878932c650526c5abe2d8e1849ef261ea643a0a858